Skip to main content
SpringerLink
Log in

WHO-Klassifikation myeloischer Neoplasien

WHO classification of myeloid neoplasms

  • Hauptreferate: Gastvorträge der Arbeitsgemeinschaften
  • Published:
Der Pathologe Aims and scope Submit manuscript

Zusammenfassung

2014 trafen sich zwei Beratungskomitees (je eines für die myeloischen und die lymphatischen Neoplasien) bestehend aus etwa 100 Pathologen, Hämatologen, Onkologen und Genetikern in Chicago zur Überarbeitung der diagnostischen WHO-Kriterien. Ziel war es, Krankheitsentitäten zu definieren, die aufgrund neuer Erkenntnisse modifiziert, entfernt oder hinzugefügt werden sollten. Zur Verbesserung einer biologisch sinnvollen Einordnung wurde insbesondere eine Reihe neuer molekulargenetischer Marker aufgenommen, welche sich als diagnostisch und/oder prognostisch relevant herausgestellt hatten. Das hieraus notwendigerweise resultierende differenzierte diagnostische Vorgehen stellt eine Herausforderung für den Hämatopathologen dar. Nicht nur ist es eine Notwendigkeit, die Informationen eines multimodalen diagnostischen Prozesses zu bündeln und die Ergebnisse von Morphologie, Immunphänotypisierung und klinischer Information vergleichend zu werten. Es ist weiterhin essenziell, die Techniken der Fluoreszenz-in-situ-Hybridisierung und des Next Generation Sequencing in den diagnostischen Prozess zu integrieren. Die hämatopathologische Diagnostik ist durch diese weitere Ausdifferenzierung personal- und kostenintensiver geworden.

Abstract

In 2014, two advisory committees (one each for myeloid and lymphoid neoplasms) of about 100 pathologists, hematologists, oncologists, and geneticists met in Chicago to revise the WHO diagnostic criteria. The goal was to define disease entities that should be modified, removed, or added based on new insights. In particular, to improve a biologically meaningful classification, a number of new molecular genetic markers were included, which had proved to be of diagnostic and/or prognostic relevance. The resulting differentiated diagnostic procedure is a challenge for the hematopathologist. Not only is it necessary to pool the information from a multimodal diagnostic process and to compare the results of morphology, immunophenotyping, and clinical information. It is also essential to integrate the techniques of fluorescence in situ hybridization and next generation sequencing into the diagnostic process. Hematopathological diagnostics have become more labor-intensive and cost-intensive as a result of this further differentiation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Harris NL, Jaffe ES, Diebold J et al (2000) Lymphoma classification—from controvery to consensus: the REAL and WHO Classification of lymphoid neoplasms. Ann Oncol 11(Suppl 1):3–10

    Article  Google Scholar 

  2. Harris NL, Jaffe ES, Stein H et al (1994) A revised european-American classification fo lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 4:1361–1392

    Google Scholar 

  3. Swerdlow S, Campo E, Harris N et al (2008) WHO classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC, Lyon

    Google Scholar 

  4. Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391–2405

    Article  CAS  Google Scholar 

  5. Barbui T, Thiele J, Gisslinger H et al (2014) Masked polycythemia vera (mPV): results of an international study. Am J Hematol 89:52–54

    Article  CAS  Google Scholar 

  6. Thiele J, Kvasnicka HM, Müllauer L et al (2011) Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. Blood 117:5710–5718

    Article  CAS  Google Scholar 

  7. Gisslinger H, Jeryczynski G, Gisslinger B et al (2017) Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria. Leukemia 31:774–775

    Article  CAS  Google Scholar 

  8. Tefferi A, Thiele J, Vannucchi AM et al (2014) An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia 28:1407–1413

    Article  CAS  Google Scholar 

  9. Maxson JE, Gotlib J, Pollyea DA et al (2013) Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med 368:1781–1790

    Article  CAS  Google Scholar 

  10. Baccarani M, Deininger MW, Rosti G et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Blood 122:872–884

    Article  CAS  Google Scholar 

  11. Hehlmann R (2015) CML–Where do we stand in 2015? Ann Hematol 94(suppl 2):103–105

    Article  Google Scholar 

  12. Deininger MW (2015) Diagnosing and managing advanced chronic myeloid leukemia. Am Soc Clin Oncol Educ Book 35:e381–e388

    Article  Google Scholar 

  13. Valent P (2015) Diagnosis and management of mastocytosis: an emerging challenge in applied hematology. Hematology Am Soc Hematol Educ Program 2015:98–105

    Article  Google Scholar 

  14. Itzykson R, Kosmider O, Renneville A et al (2013) Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol 31:2428–2436

    Article  CAS  Google Scholar 

  15. Patnaik MM, Tefferi A (2016) Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia. Blood Cancer J 6:e393

    Article  CAS  Google Scholar 

  16. Jaiswal S, Fontanillas P, Flannick J et al (2014) Aggerelated clonal hematopoiesis associated with adverse outcomes. N Engl J Med 371:2488–2498

    Article  Google Scholar 

  17. Piazza R, Valletta S, Winkelmann N et al (2013) Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet 45:18–24

    Article  CAS  Google Scholar 

  18. Gambacorti-Passerini CB, Donadoni C, Parmiani A et al (2015) Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. Blood 125:499–503

    Article  CAS  Google Scholar 

  19. Schanz J, Tüchler H, Solé F et al (2012) New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 30:820–829

    Article  Google Scholar 

  20. Papaemmanuil E, Gerstung M, Malcovati L et al (2013) Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 122:3616–3627

    Article  CAS  Google Scholar 

  21. Haferlach T, Nagata Y, Grossmann V et al (2014) Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 28:241–247

    Article  CAS  Google Scholar 

  22. Gerstung M, Pellagatti A, Malcovati L et al (2015) Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes. Nat Commun 6:5901

    Article  CAS  Google Scholar 

  23. Malcovati L, Karimi M, Papaemmanuil E et al (2015) SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood 126:233–241

    Article  CAS  Google Scholar 

  24. Haferlach C, Mecucci C, Schnittger S et al (2009) AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. Blood 114:3024–3032

    Article  CAS  Google Scholar 

  25. Schlenk RF, Taskesen E, van Norden Y et al (2013) The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. Blood 122:1576–1582

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Pathologie, Universitätsklinikum Halle (Saale), Magdeburger Straße 14, 06112, Halle (Saale), Deutschland

    C. Wickenhauser

Authors
  1. C. Wickenhauser
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Wickenhauser.

Ethics declarations

Interessenkonflikt

C. Wickenhauser gibt an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

The supplement containing this article is not sponsored by industry.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wickenhauser, C. WHO-Klassifikation myeloischer Neoplasien. Pathologe 39 (Suppl 2), 315–318 (2018). https://doi.org/10.1007/s00292-018-0534-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00292-018-0534-7

Schlüsselwörter

Keywords

Search

Navigation